Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneurol.2010.274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PAI-1 and CHRNA1-A new molecular axis and therapeutic target in primary focal hyperhidrosis.
Mol Ther Nucleic Acids
September 2025
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, 300 George Street, New Haven, CT 06511, USA.
Polydatin ameliorates hyperhidrosis by targeting Aqp5 in a mouse model.
Front Pharmacol
August 2025
Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
Background: Primary focal hyperhidrosis (PFH) is a neurological dermatological disorder characterized by localized, excessive sweating. Current treatments have limitations, and postoperative compensatory hyperhidrosis remains a concern. Aquaporin 5 (AQP5) and neurologic factors such as Brain-Derived Neurotrophic Factor (BDNF) and Neuregulin-1 (NRG-1) are known to play key roles in sweat regulation.
View Article and Find Full Text PDFImbalance of NKCC1/KCC2 contributes to the pathogenesis of primary focal hyperhidrosis.
Neurochem Int
August 2025
Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China; Department of Thoracic Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, 350212, China. Electronic ad
Background: Primary focal hyperhidrosis (PFH) is characterized by excessive sweating in localized regions, significantly impacting patients' quality of life. The imbalance between sodium-potassium-chloride cotransporter 1 (NKCC1) and potassium-chloride cotransporter 2 (KCC2) disrupts chloride ion homeostasis, potentially contributing to the pathogenesis of PFH.
Methods: Sweat gland tissues from 76 healthy controls and 76 PFH patients were collected.
Evaluation of Cardiac Autonomic Function in Patients Undergoing Thoracoscopic Sympathetic Chain Clamping for Primary Focal Hyperhidrosis.
Med Sci (Basel)
August 2025
Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
. Heart rate variability (HRV) is the variability in the beat-by-beat heart period. Primary focal hyperhidrosis (PFHH) is a disease characterized by excessive sweat production, strongly affecting social life.
View Article and Find Full Text PDF20-Year Efficacy of Endoscopic Thoracic Sympathectomy for Primary Hyperhidrosis: A Cohort Study.
J Clin Med
July 2025
Department of Thoracic Surgery, Hospital Clinic of Barcelona, Universitat de Barcelona, 08036 Barcelona, Spain.
Primary focal hyperhidrosis, characterized by excessive sweating primarily affecting the hands and axillae, can significantly impact quality of life. Bilateral thoracic sympathectomy is the gold standard treatment, providing permanent resolution of palmar hyperhidrosis. Most studies evaluating outcomes and patient satisfaction after sympathectomy focus on short- to medium-term follow-up, typically up to 5 years.
View Article and Find Full Text PDF